Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer

The New Mexico Hpv Pap Registry Steering Committee

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: The New Mexico HPV Pap Registry was established to measure the impact of cervical cancer prevention strategies in the United States. Before widespread human papillomavirus (HPV) vaccine implementation, we established the baseline prevalence for a broad spectrum of HPV genotypes across the continuum of cervical intraepithelial neoplasia (CIN) and cancer. Methods: A population-based sample of 6,272 tissue specimens was tested for 37 HPV genotypes. The number of specimens tested within each diagnostic category was: 541 negative, 1,411 CIN grade 1 (CIN1), 2,226 CIN grade 2 (CIN2), and 2,094 CIN grade 3 (CIN3) or greater. Age-specific HPV prevalence was estimated within categories for HPV genotypes targeted by HPV vaccines. Results: The combined prevalence of HPV genotypes included in the quadrivalent and nonavalent vaccines increased from 15.3% and 29.3% in CIN1 to 58.4% and 83.7% in CIN3, respectively. Prevalence of HPV types included in both vaccines tended to decrease with increasing age for CIN1, CIN2, CIN3, and squamous cell carcinoma (SCC), most notably for CIN3 and SCC. The six most common HPV types in descending order of prevalence were HPV-16, -31, -52, -58, -33, and -39 for CIN3 and HPV-16, -18, -31, -45, -52, and -33 for invasive cancers. Conclusions: Health economic modeling of HPV vaccine impact should consider age-specific differences in HPV prevalence. Impact: Population-based HPV prevalence in CIN is not well described, but is requisite for longitudinal assessment of vaccine impact and to understand the effectiveness and performance of various cervical screening strategies in vaccinated and unvaccinated women.

Original languageEnglish (US)
Pages (from-to)230-240
Number of pages11
JournalCancer Epidemiology Biomarkers and Prevention
Volume24
Issue number1
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Uterine Cervical Neoplasms
Genotype
Cervical Intraepithelial Neoplasia
Neoplasms
Papillomavirus Vaccines
Vaccines
Human papillomavirus 16
Squamous Cell Carcinoma
Human papillomavirus 31
Human papillomavirus 18
Population
Registries
Economics
Health

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Medicine(all)

Cite this

Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer. / The New Mexico Hpv Pap Registry Steering Committee.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 24, No. 1, 01.01.2015, p. 230-240.

Research output: Contribution to journalArticle

@article{a24db3e559c54d18b914fcadc528bedb,
title = "Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer",
abstract = "Background: The New Mexico HPV Pap Registry was established to measure the impact of cervical cancer prevention strategies in the United States. Before widespread human papillomavirus (HPV) vaccine implementation, we established the baseline prevalence for a broad spectrum of HPV genotypes across the continuum of cervical intraepithelial neoplasia (CIN) and cancer. Methods: A population-based sample of 6,272 tissue specimens was tested for 37 HPV genotypes. The number of specimens tested within each diagnostic category was: 541 negative, 1,411 CIN grade 1 (CIN1), 2,226 CIN grade 2 (CIN2), and 2,094 CIN grade 3 (CIN3) or greater. Age-specific HPV prevalence was estimated within categories for HPV genotypes targeted by HPV vaccines. Results: The combined prevalence of HPV genotypes included in the quadrivalent and nonavalent vaccines increased from 15.3{\%} and 29.3{\%} in CIN1 to 58.4{\%} and 83.7{\%} in CIN3, respectively. Prevalence of HPV types included in both vaccines tended to decrease with increasing age for CIN1, CIN2, CIN3, and squamous cell carcinoma (SCC), most notably for CIN3 and SCC. The six most common HPV types in descending order of prevalence were HPV-16, -31, -52, -58, -33, and -39 for CIN3 and HPV-16, -18, -31, -45, -52, and -33 for invasive cancers. Conclusions: Health economic modeling of HPV vaccine impact should consider age-specific differences in HPV prevalence. Impact: Population-based HPV prevalence in CIN is not well described, but is requisite for longitudinal assessment of vaccine impact and to understand the effectiveness and performance of various cervical screening strategies in vaccinated and unvaccinated women.",
author = "{The New Mexico Hpv Pap Registry Steering Committee} and Joste, {Nancy E.} and Ronnett, {Brigitte M.} and Hunt, {William C.} and Amanda Pearse and Erika Langsfeld and Thomas Leete and Maryann Jaramillo and Stoler, {Mark H.} and Castle, {Philip E.} and Wheeler, {Cosette M.} and Walter Kinney and Scott Norville and Alan Waxman and David Espey and Mary Ramos and Steven Jenison and Mark Schiffman and Vicki Benard and Debbie Saslow and Kim, {Jane J.} and Jack Cuzick and Pressley, {Giovanna Rossi} and Kevin English",
year = "2015",
month = "1",
day = "1",
doi = "10.1158/1055-9965.EPI-14-0775",
language = "English (US)",
volume = "24",
pages = "230--240",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer

AU - The New Mexico Hpv Pap Registry Steering Committee

AU - Joste, Nancy E.

AU - Ronnett, Brigitte M.

AU - Hunt, William C.

AU - Pearse, Amanda

AU - Langsfeld, Erika

AU - Leete, Thomas

AU - Jaramillo, Maryann

AU - Stoler, Mark H.

AU - Castle, Philip E.

AU - Wheeler, Cosette M.

AU - Kinney, Walter

AU - Norville, Scott

AU - Waxman, Alan

AU - Espey, David

AU - Ramos, Mary

AU - Jenison, Steven

AU - Schiffman, Mark

AU - Benard, Vicki

AU - Saslow, Debbie

AU - Kim, Jane J.

AU - Cuzick, Jack

AU - Pressley, Giovanna Rossi

AU - English, Kevin

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: The New Mexico HPV Pap Registry was established to measure the impact of cervical cancer prevention strategies in the United States. Before widespread human papillomavirus (HPV) vaccine implementation, we established the baseline prevalence for a broad spectrum of HPV genotypes across the continuum of cervical intraepithelial neoplasia (CIN) and cancer. Methods: A population-based sample of 6,272 tissue specimens was tested for 37 HPV genotypes. The number of specimens tested within each diagnostic category was: 541 negative, 1,411 CIN grade 1 (CIN1), 2,226 CIN grade 2 (CIN2), and 2,094 CIN grade 3 (CIN3) or greater. Age-specific HPV prevalence was estimated within categories for HPV genotypes targeted by HPV vaccines. Results: The combined prevalence of HPV genotypes included in the quadrivalent and nonavalent vaccines increased from 15.3% and 29.3% in CIN1 to 58.4% and 83.7% in CIN3, respectively. Prevalence of HPV types included in both vaccines tended to decrease with increasing age for CIN1, CIN2, CIN3, and squamous cell carcinoma (SCC), most notably for CIN3 and SCC. The six most common HPV types in descending order of prevalence were HPV-16, -31, -52, -58, -33, and -39 for CIN3 and HPV-16, -18, -31, -45, -52, and -33 for invasive cancers. Conclusions: Health economic modeling of HPV vaccine impact should consider age-specific differences in HPV prevalence. Impact: Population-based HPV prevalence in CIN is not well described, but is requisite for longitudinal assessment of vaccine impact and to understand the effectiveness and performance of various cervical screening strategies in vaccinated and unvaccinated women.

AB - Background: The New Mexico HPV Pap Registry was established to measure the impact of cervical cancer prevention strategies in the United States. Before widespread human papillomavirus (HPV) vaccine implementation, we established the baseline prevalence for a broad spectrum of HPV genotypes across the continuum of cervical intraepithelial neoplasia (CIN) and cancer. Methods: A population-based sample of 6,272 tissue specimens was tested for 37 HPV genotypes. The number of specimens tested within each diagnostic category was: 541 negative, 1,411 CIN grade 1 (CIN1), 2,226 CIN grade 2 (CIN2), and 2,094 CIN grade 3 (CIN3) or greater. Age-specific HPV prevalence was estimated within categories for HPV genotypes targeted by HPV vaccines. Results: The combined prevalence of HPV genotypes included in the quadrivalent and nonavalent vaccines increased from 15.3% and 29.3% in CIN1 to 58.4% and 83.7% in CIN3, respectively. Prevalence of HPV types included in both vaccines tended to decrease with increasing age for CIN1, CIN2, CIN3, and squamous cell carcinoma (SCC), most notably for CIN3 and SCC. The six most common HPV types in descending order of prevalence were HPV-16, -31, -52, -58, -33, and -39 for CIN3 and HPV-16, -18, -31, -45, -52, and -33 for invasive cancers. Conclusions: Health economic modeling of HPV vaccine impact should consider age-specific differences in HPV prevalence. Impact: Population-based HPV prevalence in CIN is not well described, but is requisite for longitudinal assessment of vaccine impact and to understand the effectiveness and performance of various cervical screening strategies in vaccinated and unvaccinated women.

UR - http://www.scopus.com/inward/record.url?scp=84921033623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921033623&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-14-0775

DO - 10.1158/1055-9965.EPI-14-0775

M3 - Article

C2 - 25363635

AN - SCOPUS:84921033623

VL - 24

SP - 230

EP - 240

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 1

ER -